Bayer has decided to discontinue a phase 3 trial of its oral Factor XIa inhibitor asundexian in patients with atrial fibrillation (AF), after an interim analysis concluded the novel anticoagulant ...

Bayer is pressing ahead with a phase 3 trial of its oral Factor XIa inhibitor asundexian, a new anticoagulant, despite missing efficacy targets in two mid-stage studies. The OCEANIC trial ...

The rebuilding of its pharmaceuticals pipeline follows the recent discontinuation of key experimental drug asundexian. Bayer had backed the blood-thinning drug for stroke prevention to become the ...

Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

One of the most promising developments in this area is the oral factor XIa inhibitor, asundexian. Studies have shown that asundexian can effectively inhibit factor XIa, which is believed to play a ...